AstraZeneca Expands the Development of AZD1222 into P-III Study in the US Across All Adult Age Groups

Shots:

• AstraZeneca has expanded the development of AZD1222 into P-III D8110C00001 study to assess its safety, efficacy, and immunogenicity. BARDA has funded the P-III study to accelerate the development of the vaccine
• The P-III D8110C00001 study involves assessing of AZD1222 vs PBO for the prevention of COVID-19, in up to 30,000 participants aged ≥ 18yrs. in a ratio (2:1) across ~100 trial centers in and outside the US. Participants are being randomized to receive two doses of either AZD1222 or saline control, 4wks. apart, with twice as many participants receiving the potential vaccine than the saline control
• The company is evaluating the AZD1222 globally with late-stage clinical trials ongoing in the UK, Brazil, and South Africa, while the trials are planned to start in Japan and Russia

Click here ­to­ read full press release/ article | Ref: AstraZeneca | Image: Deccan Herald